Qiagen N.V. (QGEN): Total Assets
$6.28B
As of 2025-12-31
0.0%
3-year compound annual growth
+1.4%
5-year compound annual growth
+4.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.28B | +10.4% | 2026-03-20, Balance as of period end |
| 2024-12-31 | $5.69B | -7.0% | 2026-03-20, Balance as of period end |
| 2023-12-31 | $6.12B | -2.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $6.29B | +2.3% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $6.15B | +4.7% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $5.87B | +12.1% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $5.24B | -8.9% | 2021-03-05, Balance as of period end |
| 2018-12-31 | $5.75B | +14.1% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $5.04B | +17.0% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $4.31B | +3.1% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $4.18B | -6.2% | 2017-03-06, Balance as of period end |
| 2014-12-31 | $4.45B | +9.0% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $4.09B | 0.0% | 2015-03-02, Balance as of period end |
| 2012-12-31 | $4.09B | +9.6% | 2014-03-03, Balance as of period end |
| 2011-12-31 | $3.73B | -4.7% | 2013-03-04, Balance as of period end |
| 2010-12-31 | $3.91B | +3.1% | 2012-03-27, Balance as of period end |
| 2009-12-31 | $3.80B | n/a | 2011-03-21, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
Compare QGEN, MRNA, EXEL, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗